Pre-malignant States to Hematologic Malignancies in Firefighters

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Clonal Hematopoiesis of Indeterminate PotentialMonoclonal GammopathyNon Hodgkin LymphomaLeukemiaMultiple MyelomaPlasma Cell Disorder
Interventions
OTHER

Monoclonal Gammopathy

Whole blood will be collected at the Baseline visit to evaluate for monoclonal gammopathy through SPEP, immunofixation, and free light chains.

OTHER

Complete Blood Count with differential (CBC w/ diff)

Whole blood will be collected at the Baseline visit for CBC with differential which may inform a diagnosis of a plasma cell disorder or other hematological disorder.

OTHER

Clonal hematopoiesis (CHIP)

Whole blood will be collected at the Baseline visit to be evaluated using next generation sequencing (NGS) detection of CHIP. Deep NGS to identify mutations associated with myeloid neoplasms and CHIP will be performed using an error-correcting next generation sequencing multi-gene panel targeting genes most frequently mutated in CHIP.

Trial Locations (1)

28204

RECRUITING

Levine Cancer Institute, Charlotte

All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

lead

Wake Forest University Health Sciences

OTHER

NCT06870760 - Pre-malignant States to Hematologic Malignancies in Firefighters | Biotech Hunter | Biotech Hunter